The Thesis
Brands that wait for GLP-1 household penetration to stabilise before redesigning snack pack architecture will lose 12 to 18 months of shelf positioning to rivals who moved earlier. The window to act is now, not after the next category review.
Circana puts current GLP-1 household penetration in the US at 23 percent. Food Business News reports that 6 percent of US adults are actively taking GLP-1 drugs for weight loss or diabetes management, with 35 percent saying they want to try the drugs in the future, according to PwC data cited at a Food Business News webinar in May 2026. Those two numbers together describe a market that is already large and is pointing toward much larger. You do not need to wait for it to peak before you act.
What GLP-1 Users Actually Do to a Snack Portfolio
GLP-1 drugs suppress appetite. Users eat less per occasion. They snack less often. But they do not stop caring about taste, and many actively seek protein because the drugs accelerate muscle loss alongside fat. That combination, smaller portions and higher protein demand, maps almost exactly onto pack architecture decisions you can make today.
The demand signal for protein in snacks is visible across the trade. BeverageDaily reports that 60 percent of adult consumers take a protein enhancement or supplement and 50 percent of adults drink soda. A new brand, Proda, launched at Sprouts with 10 grams of whey protein isolate per can and zero sugar precisely because that overlap is large enough to build a category around. Hain Celestial's CEO Alison Lewis confirmed on 11 May that the company is rolling out protein-heavy products across multiple brands, including a high-protein variant of The Greek Gods yogurt launched in April. These are not coincidences. They are category-wide signals that the protein-fortified SKU is moving from premium niche to mainstream expectation.
The lower-frequency repeat dimension is harder to see in your sales data right now, but it will show up. A GLP-1 user who previously bought a 12-count multipack every ten days may now buy a 6-count every 14 days. Your total category sales may look flat or slightly down. But the unit economics of that 6-count at a higher protein claim and a modest price premium can more than offset the volume loss, if you designed the pack for that occasion in the first place.
The Revolving-Door Problem Changes Your Target Audience
Here is where the GLP-1 opportunity gets more interesting and more durable than most commercial directors assume. Food Business News reports that approximately 75 percent of GLP-1 users discontinue within two years, according to University of Pennsylvania research, and dropout rates within the first year alone exceed 50 percent, according to Suzy Badaracco of Culinary Tides. As Badaracco put it: "This 6% is a revolving 6%, that's why the 6% isn't really going up."
That revolving door means your GLP-1-optimised pack is not serving a static cohort of long-term drug users. It is serving a large and constantly refreshed population that cycles through reduced-appetite states, returns to normal eating, and then may go back onto the drug again. The smaller portion, higher-protein snack you design for them also appeals to the health-conscious mainstream who never touched a GLP-1 drug. You are not designing for a niche. You are designing for a direction of travel that the entire better-for-you snack category is already moving toward.
What Pack Architecture Redesign Actually Means
Three changes are worth prioritising, in order of difficulty and payback speed.
Portion size first. Move your core snack SKUs toward a smaller single-serve format targeted at 150 to 200 calories. This is the fastest change to execute and the most immediately legible to GLP-1 users browsing the snack aisle. Do not shrink the pack silently and keep the price the same. That is what the industry calls shrinkflation, and consumers notice. Price the smaller pack lower in absolute terms but higher per gram, and communicate the portion rationale on-pack. "Right for one" is a cleaner message than a calorie count.
Protein fortification second. Adding 5 to 10 grams of protein to a snack SKU is a formulation project, not a portfolio project. It does not require a new brand or a new line. It requires your R&D and procurement teams to agree on a protein source that survives the processing conditions of your existing format. Whey isolate, pea protein, and precision-fermentation caseins are all moving down the cost curve. Aux Labs, a Canadian precision fermentation startup, raised $4 million specifically by designing its animal-free casein to work inside existing brewing infrastructure rather than bespoke plants, which signals that ingredient cost and scalability are improving faster than most snack manufacturers have modelled.
Pack count architecture third. Rethink your multipack offerings. A GLP-1 user buying for the household is not the same as a GLP-1 user buying for themselves. A 6-count individual snack pack at a higher price per unit serves the individual occasion. A 12-count or 18-count variety multipack at a modest per-unit discount serves the household where one or more members may be on the drug at any given time. Both can coexist on shelf. The mistake is to offer only the 24-count value pack that made sense for a household eating at full appetite frequency.
The Sceptic's Objection
A sceptical commercial director will raise the following: "GLP-1 penetration is still a small share of the population. Redesigning pack architecture for 6 percent of current users while 94 percent are buying our existing formats is a distraction. We should focus on the mainstream."
That objection misreads the math. The 23 percent household penetration figure from Circana is the relevant number, not the 6 percent active-user figure. A household where one person is on a GLP-1 drug changes how the entire household shops for snacks. The gateway shopper, the person filling the cart, modifies their buying behaviour for everyone in the home. And the 35 percent who say they want to try the drugs in the future are already paying attention to protein content and portion size before they ever pick up a prescription.
Beyond that, the broader CPG growth picture makes the "focus on the mainstream" argument weaker than it looks. A McKinsey report cited by Food Business News shows volume growth for the food and beverage sector sits below 1 percent annually, far short of historical performance, and total shareholder return for major global CPG players is down roughly 7 percent since 2023 while the S&P 500 is up 9 percent. The mainstream is not a safe harbour. The growth is in the segments moving toward health, function, and portion control.
What You Should Do Next Week
Pull your snack portfolio's 6-count and single-serve formats and calculate what share of your snack sales they represent today. If it is below 25 percent, your pack architecture is already behind where the market is heading.Brief your R&D team to scope protein addition to your two best-selling snack SKUs. You do not need a new brand. You need a reformulation brief and a cost model.
Talk to your category buyer at the top two retailers where you trade. Ask them directly: are GLP-1 users showing up in their snack purchase data as a distinct behaviour pattern? Retailers with loyalty card data can see this. If they can, they are already thinking about shelf resets. You want to be in that conversation before the planogram is drawn, not after.
The snack aisle is being reorganised around a smaller appetite and a higher protein expectation. The brands that move the architecture now will own the facing. The brands that wait will be looking for space on a shelf that was already reset without them.